AstraZeneca has announced the unveiling of its newly-expanded, state-of-the-art manufacturing facility in Coppell, Texas. The expansion project will double the production of Lokelma for the benefit of patients in the US and around the world.

The investment of USD 445 million to expand the facility follows the ground-breaking last week at AstraZeneca’s manufacturing facility in Albemarle County, Virginia. Both are part of AstraZeneca’s USD 50 Billion investment in US R&D and manufacturing over the next five years that was announced in July 2025.

Speaking in this regard, Jim Fox, Senior Vice President, Americas Supply Operations, AstraZeneca, said, “Our manufacturing facility in Coppell serves as both a critical pillar in global healthcare and has played an important role in supporting the local workforce over the past 10 years. The expansion underscores our commitment to patients and support for Texas’s long-term vision for scientific growth and innovation.”